pfizer glp 1 news Pfizer, Novo Nordisk bidding war is just the latest escalation of a lucrative GLP-1 race Pfizer discontinues GLP-1 pill trial,

Cross-trial comparisons remain observational, not head-to-head

doi: 10.1016/j.freeradbiomed.2023.12.031 312 FangLYanYXuZHeZZhouSJiangXet al

Its trial-derived safety profile to date is dominated by the expected GLP-1 gastrointestinal effects, generally mild to moderate and worst during dose escalation, but long-term and real-world safety the kind that only emerges after wide, prolonged use is by definition not yet available

As previously described 21 , four microliters (4 g) of reconstituted peptides were loaded and washed on a Pepmap100 C18 trap (5 m, 0.3 5.0 mm, Thermo Fisher Scientific, Waltham, MA, USA) at a flow rate of 20 L/min